ClinicalTrials.gg
CompletedNCT01645332Updated Oct 8, 2014

Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus

A Phase 3 interventional study of Placebo of DLBS3233 and DLBS3233 in Type-2-diabetes Mellitus and New Onset, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-10-08.

Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia — 9 open to participants now, 10 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Indonesia.

Enrollment
24th of 52
104 · median 85
Started
2012
with 1 other
Phase 3
9 of 66
1 open now
Registered
20th of 66
by date
Lead sponsor
5 of 66
Dexa Medica Group

Among the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, this one is the 24th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2012, is one of 9 in phase 3, and was the 20th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

9 of the 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Diabetes Mellitus, Type 2 with a site in Indonesia, or all of them as a file.
02

Study summary

This is a 2-arm, double-blind, parallel, randomized, placebo-controlled clinical study, with 12 weeks of therapy to evaluate the efficacy and safety of DLBS3233 in improving metabolic control in newly diagnosed type-2-diabetic patients, as measured by A1c level, fasting and 2-hours post-prandial plasma glucose, fasting insulin level, HOMA-IR, HOMA-B, adiponectin level, lipid profile, and body weight.

Read the detailed description

There will be two groups of treatment in this study who will receive DLBS3233 or placebo of DLBS3233 (with lifestyle modification) for 12 weeks of therapy.

Clinical and physical examination to evaluate the efficacy and safety as well as measurement of fasting and 2-hour post-prandial plasma glucose level will be performed at baseline and every 6-weeks-interval. Other clinical and laboratory examinations will be performed at baseline and at the end of study.

03

Conditions studied

  • Type-2-diabetes Mellitus
  • New Onset

Keywords

  • DLBS3233
  • new onset
  • type-2-diabetes mellitus
  • oral anti-hyperglycemic agent
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with age of 18-60 years
  • ≥ 18.5 kg/m2
  • Newly diagnosed (new onset of) type 2 DM subjects, defined as FPG level of ≥ 126 mg/dL or 2h-PG level of ≥ 200 mg/dL or A1c of ≥ 6.5%)
  • FPG ≤ 183 mg/dL
  • level of ≥ 10.0 g/dL
  • Serum ≤ 2.5 times
  • Serum creatinine \< 1.5 times upper limit of normal

Exclusion criteria

Exclusion Criteria:

  • Female of
  • Subjects with symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or other symptomatic ischemic arterial diseases necessitating medical treatment
  • Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg)
  • History of renal and/or liver disease
  • History of or the presence of any clinical evidence of
  • Presence of exacerbation of chronic illnesses, severe and acute infections, complicated infections
  • Current treatment with systemic or herbal (alternative) medicines
  • Participation in any other intervention trial within 30 days prior to Screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Placebo comparator
    Treatment I (control)

    Placebo of DLBS3233 once daily for 12 weeks + lifestyle modification

    Drug: Placebo of DLBS3233 · Other: Lifestyle modification

  • Experimental
    Treatment II

    100 mg DLBS3233 once daily for 12 weeks + lifestyle modification

    Drug: DLBS3233 · Other: Lifestyle modification

Interventions

  • DrugPlacebo of DLBS3233

    Placebo of DLBS3233 once daily for 12 weeks

    Also known as: Placebo of Inlacin

  • 100 mg DLBS3233 once daily for 12 weeks

    Also known as: Inlacin

  • OtherLifestyle modification

    Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.

06

What researchers measure

Primary outcomes

  1. Reduction of A1c level

    Reduction of A1c level from baseline to Week 12 of treatment

    Time frame: 12 weeks

Secondary outcomes

  1. Reduction of venous FPG

    Reduction of venous FPG from baseline to Week 6 and Week 12 of treatment

    Time frame: 6 weeks and 12 weeks

  2. Reduction of venous 2h-PG

    Reduction of venous 2h-PG from baseline to Week 6 and Week 12 of treatment

    Time frame: 6 weeks and 12 weeks

  3. Response rate

    Percentage of subjects with FPG \< 110 mg/dL and/or reduction of at least 10% in FPG level from baseline to Week 12 of treatment

    Time frame: 12 weeks

  4. Change in fasting insulin level

    Change in fasting insulin level from baseline to Week 12 of treatment

    Time frame: 12 weeks

  5. Change in HOMA-IR

    Change in HOMA-IR from baseline to Week 12 of treatment

    Time frame: 12 weeks

  6. Change in HOMA-B

    Change in HOMA-B from baseline to Week 12 of treatment

    Time frame: 12 weeks

  7. Change in adiponectin level

    Change in adiponectin level from baseline to Week 12 of treatment

    Time frame: 12 weeks

  8. Change in lipid profile

    Change in lipid profile (LDL-cholesterol, HDL-cholesterol, total cholesterol, and triglyceride levels) from baseline to Week 12 of treatment

    Time frame: 12 weeks

  9. Change in body weight

    Change in body weight from baseline to Week 6 and Week 12 of treatment

    Time frame: 6 weeks and 12 weeks

  10. Vital signs

    Vital signs (blood pressure, heart rate, respiratory rate) will be measured at baseline, Week 6, and Week 12

    Time frame: 6 weeks and 12 weeks

  11. Liver function

    Liver function (serum ALT, serum AST, serum γ-glutamyl transferase levels) will be evaluated at baseline and Week 12

    Time frame: 12 weeks

  12. Renal function

    Renal function (serum creatinine level) will be evaluated at baseline and Week 12

    Time frame: 12 weeks

  13. Electrocardiography (ECG)

    ECG will be evaluated at baseline and Week 12

    Time frame: 12 weeks

  14. Adverse events

    Adverse events as well as number of subjects experienced the events will be observed and evaluated throughout study period (12 weeks) and until all adverse events have been recovered or stabilized

    Time frame: 12 weeks

07

Study locations

1 site
  • Division of Endocrinology, Department of Internal Medicine, Dr. Kariadi Hospital
    Semarang, Jawa Tengah 50231, Indonesia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Aug 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2012
First posted
Jul 20, 2012
Start
Jul 2012
Primary completionActual
Aug 2014
CompletionActual
Sep 2014
Last update
Oct 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01645332
Lead sponsor
Dexa Medica Group
Responsible party
Sponsor
First posted
Jul 20, 2012
Start date
Jul 2012
Primary completion
Aug 2014
Completion
Sep 2014
Last update
Oct 8, 2014

Study contacts

Heri Nugroho, Dr,dr,SpPD,KEMD,FINASIM
principal investigator · Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital, Semarang, Indonesia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DLBS3233

Start the discussion